Business · 21/10/2009
FDA Publishes Guidance for Cardiac Allograft Gene Expression Profiling Test Systems
The FDA has released a guidance document outlining requirements for cardiac allograft gene expression profiling test systems, which are classified as Class II devices, to ensure compliance with special controls and labeling regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →